<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 01 Apr 2025 01:02:58 +0000</lastbuilddate>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Srsf3-Dependent APA Drives Macrophage Maturation and Limits Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40160097/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study reveals that Srsf3-dependent generation of long 3' untranslated region is required for efficient mitochondrial translation, which promotes mature phagocytic macrophage formation, thereby playing a protective role in atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 31. doi: 10.1161/CIRCRESAHA.124.326111. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Circulating monocytes largely contribute to macrophage buildup in atheromata, which is crucial for clearing subendothelial LDLs (low-density lipoproteins) and dead cells; however, the transitional trajectory from monocytes to macrophages in atherosclerotic plaques and the underlying regulatory mechanism remain unclear. Moreover, the role of alternative polyadenylation, a posttranscriptional regulator of cell fate, in monocyte/macrophage fate decisions during atherogenesis is not entirely understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To identify monocyte/macrophage subtypes in atherosclerotic lesions and the effect of alternative polyadenylation on these subtypes and atherogenesis, single-cell RNA sequencing, 3'-end sequencing, flow cytometric, and histopathologic analyses were performed on plaques obtained from <i>Apoe</i><sup><i>-/-</i></sup> mouse arteries with or without myeloid deletion of <i>Srsf3</i> (serine/arginine-rich splicing factor 3). Cell fractionation, polysome profiling, L-azidohomoalanine metabolic labeling assay, and metabolomic profiling were conducted to disclose the underlying mechanisms. Reprogramming of widespread alternative polyadenylation patterns was estimated in human plaques via bulk RNA sequencing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified a subset of lesional cells in a monocyte-to-macrophage transitional state, which exhibited high expression of chemokines in mice. <i>Srsf3</i> deletion caused a maturation delay of these transitional cells and phagocytic impairment of lesional macrophages, aggravating atherosclerosis. Mechanistically, <i>Srsf3</i> deficiency shortened 3' untranslated regions of mitochondria-associated Aars2 (alanyl-tRNA synthetase 2), disrupting its translation. The resultant impairment of protein synthesis in mitochondria led to mitochondrial dysfunction with declined NAD<sup>+</sup> levels, activation of the integrated stress response, and metabolic reprogramming in macrophages. Administering an NAD<sup>+</sup> precursor nicotinamide mononucleotide or the integrated stress response inhibitor partially restored <i>Srsf3</i>-deficient macrophage maturation, and nicotinamide mononucleotide treatment mitigated the proatherosclerotic effects of <i>Srsf3</i> deficiency. Consistently, <i>Srsf3</i> downregulation, global 3' untranslated region shortening, and accumulation of these transitional macrophages were associated with atherosclerosis progression in humans.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study reveals that Srsf3-dependent generation of long 3' untranslated region is required for efficient mitochondrial translation, which promotes mature phagocytic macrophage formation, thereby playing a protective role in atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40160097/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40160097</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.326111>10.1161/CIRCRESAHA.124.326111</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40160097</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Xian Yang</dc:creator>
<dc:creator>Xin Zhang</dc:creator>
<dc:creator>Yaru Tian</dc:creator>
<dc:creator>Jiaxuan Yang</dc:creator>
<dc:creator>Yunhui Jia</dc:creator>
<dc:creator>Yuhuai Xie</dc:creator>
<dc:creator>Lianping Cheng</dc:creator>
<dc:creator>Shenglai Chen</dc:creator>
<dc:creator>Linfeng Wu</dc:creator>
<dc:creator>Yihong Qin</dc:creator>
<dc:creator>Zhen Zhao</dc:creator>
<dc:creator>Dejian Zhao</dc:creator>
<dc:creator>Yuanyuan Wei</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Srsf3-Dependent APA Drives Macrophage Maturation and Limits Atherosclerosis</dc:title>
<dc:identifier>pmid:40160097</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.326111</dc:identifier>
</item>
<item>
<title>Predicting imminent ventricular arrhythmias from ambulatory ECG signals: far-reaching or too far to reach?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40159411/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 30:ehaf008. doi: 10.1093/eurheartj/ehaf008. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40159411/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40159411</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf008>10.1093/eurheartj/ehaf008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40159411</guid>
<pubDate>Sun, 30 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Konstantinos C Siontis</dc:creator>
<dc:creator>Paul A Friedman</dc:creator>
<dc:date>2025-03-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Predicting imminent ventricular arrhythmias from ambulatory ECG signals: far-reaching or too far to reach?</dc:title>
<dc:identifier>pmid:40159411</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf008</dc:identifier>
</item>
<item>
<title>Deep learning-quantified body composition from positron emission tomography/computed tomography and cardiovascular outcomes: a multicentre study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40159388/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Volumetric body tissue composition can be obtained rapidly and automatically from standard cardiac PET/CT. This new information provides a detailed, quantitative assessment of sarcopenia and cardiometabolic health for physicians.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 30:ehaf131. doi: 10.1093/eurheartj/ehaf131. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Positron emission tomography (PET)/computed tomography (CT) myocardial perfusion imaging (MPI) is a vital diagnostic tool, especially in patients with cardiometabolic syndrome. Low-dose CT scans are routinely performed with PET for attenuation correction and potentially contain valuable data about body tissue composition. Deep learning and image processing were combined to automatically quantify skeletal muscle (SM), bone and adipose tissue from these scans and then evaluate their associations with death or myocardial infarction (MI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In PET MPI from three sites, deep learning quantified SM, bone, epicardial adipose tissue (EAT), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and intermuscular adipose tissue (IMAT). Sex-specific thresholds for abnormal values were established. Associations with death or MI were evaluated using unadjusted and multivariable models adjusted for clinical and imaging factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 10 085 patients, with median age 68 (interquartile range 59-76) and 5767 (57%) male. Body tissue segmentations were completed in 102 ± 4 s. Higher VAT density was associated with an increased risk of death or MI in both unadjusted [hazard ratio (HR) 1.40, 95% confidence interval (CI) 1.37-1.43] and adjusted (HR 1.24, 95% CI 1.19-1.28) analyses, with similar findings for IMAT, SAT, and EAT. Patients with elevated VAT density and reduced myocardial flow reserve had a significantly increased risk of death or MI (adjusted HR 2.49, 95% CI 2.23-2.77).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Volumetric body tissue composition can be obtained rapidly and automatically from standard cardiac PET/CT. This new information provides a detailed, quantitative assessment of sarcopenia and cardiometabolic health for physicians.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40159388/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40159388</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf131>10.1093/eurheartj/ehaf131</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40159388</guid>
<pubDate>Sun, 30 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Robert J H Miller</dc:creator>
<dc:creator>Jirong Yi</dc:creator>
<dc:creator>Aakash Shanbhag</dc:creator>
<dc:creator>Anna Marcinkiewicz</dc:creator>
<dc:creator>Krishna K Patel</dc:creator>
<dc:creator>Mark Lemley</dc:creator>
<dc:creator>Giselle Ramirez</dc:creator>
<dc:creator>Jolien Geers</dc:creator>
<dc:creator>Panithaya Chareonthaitawee</dc:creator>
<dc:creator>Samuel Wopperer</dc:creator>
<dc:creator>Daniel S Berman</dc:creator>
<dc:creator>Marcelo Di Carli</dc:creator>
<dc:creator>Damini Dey</dc:creator>
<dc:creator>Piotr J Slomka</dc:creator>
<dc:date>2025-03-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deep learning-quantified body composition from positron emission tomography/computed tomography and cardiovascular outcomes: a multicentre study</dc:title>
<dc:identifier>pmid:40159388</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf131</dc:identifier>
</item>
<item>
<title>Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40159247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among patients with HFmrEF/HFpEF in the FINEARTS-HF randomized clinical trial, higher proportions of cardiovascular and overall mortality in those with EF less than 50% were related principally to higher proportions of sudden death. A clear treatment effect of finerenone on cardiovascular or cause-specific mortality was not identified, although the trial was likely underpowered for these outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 30. doi: 10.1001/jamacardio.2025.0860. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The mode of death in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) remains poorly understood and may vary by EF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the mode of death according to EF and the treatment effect of finerenone on cause-specific mortality in patients with HFmrEF/HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial, which evaluated clinical outcomes in 6001 patients with HF and EF greater than or equal to 40% randomly assigned to finerenone or placebo. The mode of death in relation to baseline EF categories (&lt;50%, ≥50-&lt;60%, and ≥60%) was examined, and the effect of randomized treatment on cause-specific death in Cox regression models was assessed. Data analysis was conducted between September 2024 and January 2025.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Finerenone vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Mode of death as centrally adjudicated by a clinical end points committee.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1013 patients (16.9%; median [IQR] age, 76 [69-82] years; 594 male [58.6%]) who died during median (IQR) follow-up of 32 (23-36) months, mode of death was ascribed to cardiovascular causes in 502 (49.6%), noncardiovascular causes in 368 (36.3%), and undetermined cause in 143 (14.1%). Of cardiovascular deaths, 215 (42.8%) were due to sudden death, 163 (32.4%) to HF, 48 (9.6%) to stroke, 25 (5.0%) to myocardial infarction, and 51 (10.2%) to other cardiovascular causes. The proportion of all-cause, cardiovascular, and sudden death was higher in those with EF less than 50%. The proportion of deaths related to HF was similar across EF categories, and the proportion of deaths due to myocardial infarction, stroke, and other cardiovascular causes was low regardless of EF. Randomization to finerenone did not significantly reduce death or cause-specific death compared with placebo in any EF category.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among patients with HFmrEF/HFpEF in the FINEARTS-HF randomized clinical trial, higher proportions of cardiovascular and overall mortality in those with EF less than 50% were related principally to higher proportions of sudden death. A clear treatment effect of finerenone on cardiovascular or cause-specific mortality was not identified, although the trial was likely underpowered for these outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40159247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40159247</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0860>10.1001/jamacardio.2025.0860</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40159247</guid>
<pubDate>Sun, 30 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Jonathan W Cunningham</dc:creator>
<dc:creator>Maria A Pabon</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Flaviana Amarante</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Markus F Scheerer</dc:creator>
<dc:creator>Andrea Lage</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2025-03-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40159247</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0860</dc:identifier>
</item>
<item>
<title>Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: a Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40159132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this first study of EPN in valvular heart disease, EPN increased rates of AVR for severe AS, lessened gender and age disparities in AVR utilization, and improved survival time. EPN may provide a simple, scalable intervention to raise awareness of critical TTE findings and improve the quality of care for severe AS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 30. doi: 10.1161/CIRCULATIONAHA.125.074470. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. We evaluate the impact of electronic provider notifications (EPN) on rates of AVR at 1-year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a pragmatic cluster randomized clinical trial conducted within multicenter academic health system from March 2022 through November 2023, 285 providers who had ordered a transthoracic echocardiogram (TTE) with findings potentially indicative of severe AS with aortic valve area ≤ 1.0 cm<sup>2</sup> were enrolled. Providers were randomly assigned to receive EPN for each of their patients with severe AS on TTE or to usual care. Notifications highlighted the detection of severe AS and included patient-specific clinical guideline recommendations for its management. The primary endpoint was the proportion of patients with severe AS receiving AVR within 1-year of the index TTE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 144 providers were randomized to intervention and 141 to control, resulting in 496 and 443 patients assigned to each group, respectively. The patient cohort had mean age of 77±11 years, was 47% female, and had mean aortic valve area 0.8±0.1 cm<sup>2</sup>. Rates of AVR within 1-year were 48.2% with EPN versus 37.2% with usual care (OR 1.62; 95% CI 1.13-2.32; p=0.009) and 60.7% and 46.5%, respectively, amongst symptomatic patients (OR 1.77; 95% CI 1.17-2.65; p=0.006). Notification treatment effect was highest with EPN in patients >;80 years of age (OR 2.00; 95% CI 1.17-3.41; p=0.01), in women (OR 2.78; 95% CI 1.69-4.57; p&lt;0.001), and when index TTE was performed within the inpatient setting (OR 2.49, 95% CI 1.44-4.31; p&lt;0.001). Within 1-year, restricted mean survival time was longer with EPN in all (12 days; p=0.04) and symptomatic patients (23 days; p=0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this first study of EPN in valvular heart disease, EPN increased rates of AVR for severe AS, lessened gender and age disparities in AVR utilization, and improved survival time. EPN may provide a simple, scalable intervention to raise awareness of critical TTE findings and improve the quality of care for severe AS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40159132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40159132</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.074470>10.1161/CIRCULATIONAHA.125.074470</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40159132</guid>
<pubDate>Sun, 30 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Varsha Keelara Tanguturi</dc:creator>
<dc:creator>Roukoz Abou-Karam</dc:creator>
<dc:creator>Fangzhou Cheng</dc:creator>
<dc:creator>Rong Duan</dc:creator>
<dc:creator>Ignacio Inglessis</dc:creator>
<dc:creator>Nathaniel Langer</dc:creator>
<dc:creator>Evin Yucel</dc:creator>
<dc:creator>Jonathan Passeri</dc:creator>
<dc:creator>Judy Hung</dc:creator>
<dc:creator>Sammy Elmariah</dc:creator>
<dc:date>2025-03-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: a Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40159132</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.074470</dc:identifier>
</item>
<item>
<title>Two-year Outcomes of Transcatheter Edge-to-edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40159089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: At 2-year follow-up, tricuspid TEER appears safe, significantly reduced TR severity, and decreased rates of HFH compared with medical therapy alone.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 30. doi: 10.1161/CIRCULATIONAHA.125.074536. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: One-year outcomes of the TRILUMINATE Pivotal trial found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid regurgitation (TR) improved quality-of-life compared with medical therapy alone with similar rates of mortality and heart failure hospitalization (HFH). However, additional follow-up is necessary to determine prolonged benefits of tricuspid TEER.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 572 patients with severe, symptomatic TR were randomized to either tricuspid TEER+medical therapy (Device) or medical therapy alone (Control). Two-year prespecified endpoints were (1) recurrent HFH and (2) freedom from all-cause mortality, tricuspid valve surgery and tricuspid valve intervention post treatment visit, assessed in the intention-to-treat population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The annualized rate of recurrent heart failure hospitalizations through 2 years was significantly lower with tricuspid TEER compared with Control (0.19 vs 0.26 events/patient-year, p=0.02; joint frailty model hazard ratio 0.72, one-sided upper confidence limit of 0.93, p=0.02). Freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve intervention through 2 years was significantly higher with tricuspid TEER compared with Control (77.6% vs 29.3%, p&lt;0.0001) driven by more tricuspid valve intervention in control patients crossing over to device treatment (3.8% vs. 61.5%). Rates of all-cause mortality (17.9% vs. 17.1%) and tricuspid valve surgery (2.3% vs. 4.3%) were similar between groups. Moderate-or-less TR was present in 84% at 2 years in the Device group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: At 2-year follow-up, tricuspid TEER appears safe, significantly reduced TR severity, and decreased rates of HFH compared with medical therapy alone.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40159089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40159089</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.074536>10.1161/CIRCULATIONAHA.125.074536</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40159089</guid>
<pubDate>Sun, 30 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Saibal Kar</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:creator>Brian K Whisenant</dc:creator>
<dc:creator>Nadira Hamid</dc:creator>
<dc:creator>Hursh Naik</dc:creator>
<dc:creator>Peter Tadros</dc:creator>
<dc:creator>Matthew J Price</dc:creator>
<dc:creator>Gagan Singh</dc:creator>
<dc:creator>Jonathan G Schwartz</dc:creator>
<dc:creator>Samir Kapadia</dc:creator>
<dc:creator>Oluseun Alli</dc:creator>
<dc:creator>Samuel Horr</dc:creator>
<dc:creator>Puvi Seshiah</dc:creator>
<dc:creator>Wayne Batchelor</dc:creator>
<dc:creator>Brandon M Jones</dc:creator>
<dc:creator>Mustafa I Ahmed</dc:creator>
<dc:creator>Raymond Benza</dc:creator>
<dc:creator>Ulrich Jorde</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Andrew A Ghobrial</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Phillip M Trusty</dc:creator>
<dc:creator>Dina Huang</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>David H Adams</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>TRILUMINATE pivotal investigators</dc:creator>
<dc:date>2025-03-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Two-year Outcomes of Transcatheter Edge-to-edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Trial</dc:title>
<dc:identifier>pmid:40159089</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.074536</dc:identifier>
</item>
<item>
<title>5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40158212/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: At 5 years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke. Valve durability and performance were excellent in both arms. This midterm evaluation reinforces the position of TAVR as noninferior to surgery in patients with severe aortic stenosis at low surgical risk (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 21:S0735-1097(25)05335-5. doi: 10.1016/j.jacc.2025.03.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The Evolut Low Risk trial demonstrated that transcatheter aortic valve replacement (TAVR) was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at 2 years. Outcomes at 5 years have not been reported.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate 5-year clinical and hemodynamic outcomes with TAVR vs surgery in patients from the Evolut Low Risk trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We randomly assigned low-risk patients with severe aortic stenosis to TAVR or surgery. The primary endpoint was a composite of all-cause mortality or disabling stroke. Secondary endpoints included clinical, echocardiographic, and quality-of-life outcomes through 5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1,414 patients underwent an attempted implant (n = 730 TAVR, n = 684 surgery). The mean age was 74 years (range 51-88 years), and women accounted for 35% of patients. At 5 years the Kaplan-Meier estimate for the primary endpoint of all-cause mortality or disabling stroke was 15.5% for the TAVR group and 16.4% for the surgery group (P = 0.47). The Kaplan-Meier estimates in the TAVR and surgery groups for all-cause mortality were 13.5% and 14.9% (P = 0.39) and for disabling stroke were 3.6% and 4.0% (P = 0.57). Cardiovascular mortality was 7.2% in the TAVR group and 9.3% in the surgery group (P = 0.15). Noncardiovascular mortality in the TAVR group was 6.8% and 6.2% in the surgery group (P = 0.73). A site-level vital status sweep was performed for patients who were lost to follow-up or withdrew from the study. With the addition of these patients, the all-cause mortality rate at 5 years for patients undergoing TAVR was 14.7% and for surgery was 15.2% (P = 0.74). Over 5 years, valve reintervention rate was 3.3% for TAVR and 2.5% for surgery (P = 0.44). A sustained improvement in quality of life was observed in both treatment arms with mean Kansas City Cardiomyopathy Questionnaire summary score of 88.3 ± 15.8 in TAVR and 88.5 ± 15.8 in surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: At 5 years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke. Valve durability and performance were excellent in both arms. This midterm evaluation reinforces the position of TAVR as noninferior to surgery in patients with severe aortic stenosis at low surgical risk (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40158212/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40158212</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.004>10.1016/j.jacc.2025.03.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40158212</guid>
<pubDate>Sun, 30 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>John K Forrest</dc:creator>
<dc:creator>Steven J Yakubov</dc:creator>
<dc:creator>G Michael Deeb</dc:creator>
<dc:creator>Hemal Gada</dc:creator>
<dc:creator>Mubashir A Mumtaz</dc:creator>
<dc:creator>Basel Ramlawi</dc:creator>
<dc:creator>Tanvir Bajwa</dc:creator>
<dc:creator>John Crouch</dc:creator>
<dc:creator>William Merhi</dc:creator>
<dc:creator>Stephane Leung Wai Sang</dc:creator>
<dc:creator>Neal S Kleiman</dc:creator>
<dc:creator>George Petrossian</dc:creator>
<dc:creator>Newell B Robinson</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>Ayman Iskander</dc:creator>
<dc:creator>Pierre Berthoumieu</dc:creator>
<dc:creator>Didier Tchétché</dc:creator>
<dc:creator>Christopher Feindel</dc:creator>
<dc:creator>Eric M Horlick</dc:creator>
<dc:creator>Shigeru Saito</dc:creator>
<dc:creator>Jae K Oh</dc:creator>
<dc:creator>Yoojin Jung</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:creator>Low Risk Trial Investigators</dc:creator>
<dc:date>2025-03-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis</dc:title>
<dc:identifier>pmid:40158212</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.004</dc:identifier>
</item>
<item>
<title>Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40158211/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Solbinsiran inhibits hepatic ANGPTL3 translation and results in significant reductions in all atherogenic lipoproteins in mixed dyslipidemia. The impact of this approach on cardiovascular outcomes remains to be determined. (A Study of LY3561774 in Participants With Dyslipidemia; NCT04644809).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 27:S0735-1097(25)05336-7. doi: 10.1016/j.jacc.2025.03.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The residual cardiovascular risk associated with hypertriglyceridemia and remnant particles supports efforts to develop effective novel therapeutic approaches. Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases, and Mendelian randomization studies associate lower ANGPTL3 activity with lower triglycerides, and lower cardiovascular risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to evaluate the impact of solbinsiran, an N-acetylgalactosamine-conjugated small interfering RNA developed to inhibit hepatic translation of ANGPTL3 messenger RNA (mRNA), on ANGPTL3 and lipid levels in preclinical models and humans.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In preclinical studies, the impact of solbinsiran on ANGPTL3 levels was assessed in mouse and nonhuman primate models. The phase 1 clinical study enrolled participants with mixed dyslipidemia. In the single-ascending-dose study, participants received single subcutaneous doses of solbinsiran (24-960 mg) or matching placebo. In the repeat-dose study, subcutaneous solbinsiran (208 or 480 mg) or matching placebo on days 1 and 29 was evaluated. Safety, pharmacokinetics, and effect on levels of ANGPTL3 and lipid parameters were evaluated over 169 days.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In mice transiently expressing human ANGPTL3, a single dose of solbinsiran reduced hepatocyte ANGPTL3 mRNA expression by 65% vs vehicle-treated mice. In cynomolgus monkeys, mean ± SEM reductions in hepatic ANGPTL3 mRNA expression up to 73% ± 2% (P &lt; 0.0001) and serum ANGPTL3 protein expression up to 69% ± 4% (P &lt; 0.001) were seen vs vehicle-treated monkeys. In humans, a single dose of solbinsiran resulted in dose-dependent mean ± SD percentage reductions from baseline in ANGPTL3 up to 86% ± 4%, triglycerides up to 73% ± 7%, low-density lipoprotein (LDL) cholesterol up to 30% ± 16%, non-high-density lipoprotein cholesterol up to 41% ± 12%, and apolipoprotein B up to 30% ± 11%, with sustained effects at higher doses (P &lt; 0.0001 for all). The repeat-dose study demonstrated reductions in ANGPTL3 of 89% ± 6%, triglycerides up to 70% ± 13%, LDL cholesterol up to 42% ± 14%, non-high-density lipoprotein cholesterol up to 46% ± 14%, and apolipoprotein B up to 36% ± 13% (P &lt; 0.0001 for all). Nuclear magnetic resonance lipoprotein analysis demonstrated reductions in the total number of triglyceride-rich lipoprotein and LDL particles with solbinsiran. Adverse events were mostly mild in severity, with similar incidence in solbinsiran- and placebo-treated participants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Solbinsiran inhibits hepatic ANGPTL3 translation and results in significant reductions in all atherogenic lipoproteins in mixed dyslipidemia. The impact of this approach on cardiovascular outcomes remains to be determined. (A Study of LY3561774 in Participants With Dyslipidemia; NCT04644809).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40158211/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40158211</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.005>10.1016/j.jacc.2025.03.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40158211</guid>
<pubDate>Sun, 30 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Kausik K Ray</dc:creator>
<dc:creator>Helle Linnebjerg</dc:creator>
<dc:creator>Laura F Michael</dc:creator>
<dc:creator>Xi Shen</dc:creator>
<dc:creator>Xiaosu Ma</dc:creator>
<dc:creator>Shufen Lim</dc:creator>
<dc:creator>Eugene Y Zhen</dc:creator>
<dc:creator>Henryk Dudek</dc:creator>
<dc:creator>Marc Abrams</dc:creator>
<dc:creator>Utsav Saxena</dc:creator>
<dc:creator>Anton Turanov</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Giacomo Ruotolo</dc:creator>
<dc:date>2025-03-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies</dc:title>
<dc:identifier>pmid:40158211</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.005</dc:identifier>
</item>
<item>
<title>Evolut Low-Risk Trial 5-Year Result: We're Halfway There</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40158210/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 20:S0735-1097(25)05759-6. doi: 10.1016/j.jacc.2025.03.428. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40158210/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40158210</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.428>10.1016/j.jacc.2025.03.428</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40158210</guid>
<pubDate>Sun, 30 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:creator>Alan Zajarias</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2025-03-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Evolut Low-Risk Trial 5-Year Result: We're Halfway There</dc:title>
<dc:identifier>pmid:40158210</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.428</dc:identifier>
</item>
<item>
<title>Near-term prediction of sustained ventricular arrhythmias applying artificial intelligence to single-lead ambulatory electrocardiogram</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40157386/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A novel deep learning model utilizing dynamic single-lead ambulatory ECGs accurately identifies patients at near-term risk of ventricular arrhythmias. It also uncovers an early depolarization pattern as a potential determinant of ventricular arrhythmias events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 30:ehaf073. doi: 10.1093/eurheartj/ehaf073. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Accurate near-term prediction of life-threatening ventricular arrhythmias would enable pre-emptive actions to prevent sudden cardiac arrest/death. A deep learning-enabled single-lead ambulatory electrocardiogram (ECG) may identify an ECG profile of individuals at imminent risk of sustained ventricular tachycardia (VT).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This retrospective study included 247 254, 14 day ambulatory ECG recordings from six countries. The first 24 h were used to identify patients likely to experience sustained VT occurrence (primary outcome) in the subsequent 13 days using a deep learning-based model. The development set consisted of 183 177 recordings. Performance was evaluated using internal (n = 43 580) and external (n = 20 497) validation data sets. Saliency mapping visualized features influencing the model's risk predictions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among all recordings, 1104 (.5%) had sustained ventricular arrhythmias. In both the internal and external validation sets, the model achieved an area under the receiver operating characteristic curve of .957 [95% confidence interval (CI) .943-.971] and .948 (95% CI .926-.967). For a specificity fixed at 97.0%, the sensitivity reached 70.6% and 66.1% in the internal and external validation sets, respectively. The model accurately predicted future VT occurrence of recordings with rapid sustained VT (≥180 b.p.m.) in 80.7% and 81.1%, respectively, and 90.0% of VT that degenerated into ventricular fibrillation. Saliency maps suggested the role of premature ventricular complex burden and early depolarization time as predictors for VT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A novel deep learning model utilizing dynamic single-lead ambulatory ECGs accurately identifies patients at near-term risk of ventricular arrhythmias. It also uncovers an early depolarization pattern as a potential determinant of ventricular arrhythmias events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40157386/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40157386</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf073>10.1093/eurheartj/ehaf073</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40157386</guid>
<pubDate>Sat, 29 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Laurent Fiorina</dc:creator>
<dc:creator>Tanner Carbonati</dc:creator>
<dc:creator>Kumar Narayanan</dc:creator>
<dc:creator>Jia Li</dc:creator>
<dc:creator>Christine Henry</dc:creator>
<dc:creator>Jagmeet P Singh</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:date>2025-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Near-term prediction of sustained ventricular arrhythmias applying artificial intelligence to single-lead ambulatory electrocardiogram</dc:title>
<dc:identifier>pmid:40157386</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf073</dc:identifier>
</item>
<item>
<title>Deep Learning Electrocardiogram Model for Risk Stratification of Coronary Revascularization Need in the Emergency Department</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40156923/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The model was able to detect revascularization and type 1 MI with competitive performance, suggesting a potential role to complement current clinical assessment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 29:ehaf254. doi: 10.1093/eurheartj/ehaf254. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Identification of patients with acute coronary syndrome requiring coronary revascularization can be challenging due to inconclusive electrocardiogram (ECG) findings or biomarker results. A deep learning model to detect ECG patterns associated with revascularization likelihood was developed, aiming to guide further assessment and reduce diagnostic uncertainty.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A convolutional neural network model was trained on 144,691 ED visits from a US cohort (60±19 years; 53% female; 0.6% revascularization), tested on a separate test cohort (n=35,995), and benchmarked against clinician ECG interpretation and cardiac troponin T (TnT). External validation was performed for the outcomes revascularization and type 1 myocardial infarction (MI) on 18,673 ED visits from Europe (55±21 years; 49% female; 1.5% revascularization; 1% type 1 MI). Primary performance metric was area under the receiver operating characteristic curve (AUROC).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the test cohort, the model achieved an AUROC of 0.91 (95% confidence interval [CI] 0.91-0.91), outperforming clinician ECG interpretation (AUROC 0.65, 95% CI 0.54-0.76) and conventional cardiac TnT (AUROC 0.71). In the external validation cohort, ECG model AUROC was 0.81 (95% CI 0.81-0.82) for revascularization, and 0.85 (95% CI 0.84-0.85) for type 1 MI, compared to 0.67 (95% CI 0.54-0.81) and 0.74 (95% CI 0.56-0.92) for clinician interpretation, and 0.85 and 0.87 for high-sensitivity (hs)-TnT, respectively. The ECG model had higher specificity but lower sensitivity compared to hs-TnT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The model was able to detect revascularization and type 1 MI with competitive performance, suggesting a potential role to complement current clinical assessment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40156923/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40156923</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf254>10.1093/eurheartj/ehaf254</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40156923</guid>
<pubDate>Sat, 29 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Antonius Büscher</dc:creator>
<dc:creator>Lucas Plagwitz</dc:creator>
<dc:creator>Kemal Yildirim</dc:creator>
<dc:creator>Tobias J Brix</dc:creator>
<dc:creator>Philipp Neuhaus</dc:creator>
<dc:creator>Lucas Bickmann</dc:creator>
<dc:creator>Amélie F Menke</dc:creator>
<dc:creator>Vincent F van Almsick</dc:creator>
<dc:creator>Hermann Pavenstädt</dc:creator>
<dc:creator>Philipp Kümpers</dc:creator>
<dc:creator>Dominik Heider</dc:creator>
<dc:creator>Julian Varghese</dc:creator>
<dc:creator>Lars Eckardt</dc:creator>
<dc:date>2025-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deep Learning Electrocardiogram Model for Risk Stratification of Coronary Revascularization Need in the Emergency Department</dc:title>
<dc:identifier>pmid:40156923</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf254</dc:identifier>
</item>
<item>
<title>Deep learning for echocardiographic assessment and risk stratification of aortic, mitral, and tricuspid regurgitation: the DELINEATE-Regurgitation study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40156921/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: An AI system can accurately classify AR, MR, and TR and predict MR progression beyond currently known risk factors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 29:ehaf248. doi: 10.1093/eurheartj/ehaf248. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Classification and risk stratification in aortic (AR), mitral (MR), and tricuspid regurgitation (TR) remains a significant clinical challenge. This study aimed to develop an artificial intelligence (AI) system to assess valvular regurgitation and stratify MR progression risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using transthoracic echocardiograms (TTEs) at two sites (internal development/test, external test), the DELINEATE-Regurgitation system was developed to classify AR, MR, and TR severity using color Doppler videos. Methods of summating video-level classifications into study-level predictions were tested, comparing single view with multiview approaches integrating predictions across multiple videos. Model agreement with cardiologists was assessed by weighted kappa. A separate AI system (DELINEATE-MR-Progression) analyzing color Doppler videos was developed to predict which patients with mild, mild-moderate, and moderate MR were most likely to progress to moderate-severe or severe MR with analysis by Kaplan-Meier and Cox proportional hazards models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 71,660 TTEs with 1,203,980 color Doppler videos were included. The weighted kappa in internal/external test sets for regurgitation classification was 0.81/0.76 for AR, 0.76/0.72 for MR, and 0.73/0.64 for TR using a multiview approach intaking all color Doppler videos in a study, demonstrating substantial agreement with cardiologist interpretation with superiority of multiview over single view approaches. In the progression analysis, the AI score stratified MR progression risk even when controlled for clinical factors known to be associated with MR progression (internal test set hazard ratio 4.1 [95% confidence interval 2.5-6.6]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: An AI system can accurately classify AR, MR, and TR and predict MR progression beyond currently known risk factors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40156921/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40156921</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf248>10.1093/eurheartj/ehaf248</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40156921</guid>
<pubDate>Sat, 29 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Aaron Long</dc:creator>
<dc:creator>Joshua Finer</dc:creator>
<dc:creator>Heidi Hartman</dc:creator>
<dc:creator>Dustin Hartzel</dc:creator>
<dc:creator>Linyuan Jing</dc:creator>
<dc:creator>Christopher Kelsey</dc:creator>
<dc:creator>Daniel Rocha</dc:creator>
<dc:creator>Jeffrey Ruhl</dc:creator>
<dc:creator>David vanMaanen</dc:creator>
<dc:creator>Youssef Elnabawi</dc:creator>
<dc:creator>Gil Metser</dc:creator>
<dc:creator>Eamon Duffy</dc:creator>
<dc:creator>Thomas Mawson</dc:creator>
<dc:creator>Emily Tat</dc:creator>
<dc:creator>Christopher M Haggerty</dc:creator>
<dc:creator>Mathew Maurer</dc:creator>
<dc:creator>Andrew J Einstein</dc:creator>
<dc:creator>Ashley N Beecy</dc:creator>
<dc:creator>Deepa Kumaraiah</dc:creator>
<dc:creator>Richard B Devereux</dc:creator>
<dc:creator>Shunichi Homma</dc:creator>
<dc:creator>Martin Leon</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Pierre Elias</dc:creator>
<dc:creator>Timothy J Poterucha</dc:creator>
<dc:date>2025-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deep learning for echocardiographic assessment and risk stratification of aortic, mitral, and tricuspid regurgitation: the DELINEATE-Regurgitation study</dc:title>
<dc:identifier>pmid:40156921</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf248</dc:identifier>
</item>
<item>
<title>26 mm SAPIEN fractured 23 mm SAPIEN and surgical prosthesis: a transcatheter aortic valve-in-valve-in-valve implantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40156915/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 29:ehaf173. doi: 10.1093/eurheartj/ehaf173. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40156915/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40156915</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf173>10.1093/eurheartj/ehaf173</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40156915</guid>
<pubDate>Sat, 29 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mi Chen</dc:creator>
<dc:creator>Jonathan Michel</dc:creator>
<dc:creator>Albert Markus Kasel</dc:creator>
<dc:date>2025-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>26 mm SAPIEN fractured 23 mm SAPIEN and surgical prosthesis: a transcatheter aortic valve-in-valve-in-valve implantation</dc:title>
<dc:identifier>pmid:40156915</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf173</dc:identifier>
</item>
<item>
<title>Unveiling the hidden force behind long-term survival in type A interrupted aortic arch: the pervasive collateral circulation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40156899/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 29:ehaf188. doi: 10.1093/eurheartj/ehaf188. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40156899/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40156899</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf188>10.1093/eurheartj/ehaf188</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40156899</guid>
<pubDate>Sat, 29 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Rong Wang</dc:creator>
<dc:creator>Hongliang Li</dc:creator>
<dc:creator>Qingyu Ji</dc:creator>
<dc:date>2025-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Unveiling the hidden force behind long-term survival in type A interrupted aortic arch: the pervasive collateral circulation</dc:title>
<dc:identifier>pmid:40156899</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf188</dc:identifier>
</item>
<item>
<title>Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40156843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Oral semaglutide reduced MACE outcomes independently of concomitant SGLT2i treatment and this combination appeared to be safe.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 29. doi: 10.1161/CIRCULATIONAHA.125.074545. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Both glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) improve cardiovascular (CV) outcomes in people with type 2 diabetes (T2D) and CV or chronic kidney disease (CKD). However, there are limited data about the effect of combining these agents on CV and safety outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The SOUL trial (NCT03914326) randomised 9650 participants with T2D and atherosclerotic CV disease and/or CKD to oral semaglutide or placebo. As prespecified, participants were analysed according to baseline use of SGLT2i (Yes: n=2596, No: n=7054) and, subsequently for any use of SGLT2i during the trial (Yes: n=4718, No: n=4932). The primary outcome was time to first major adverse cardiovascular event (MACE), defined as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. Safety was evaluated by comparing the incidence of serious adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a mean follow-up of 47.5±10.9 months, the risk of the primary outcome in the overall trial population was 14% lower for oral semaglutide vs placebo (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.77; 0.96). In those taking SGLT2i at baseline, there were 143/1296 (semaglutide) versus 158/1300 (placebo) primary outcome events (HR 0.89; 95% CI 0.71; 1.11); and 436/3529 versus 510/3525, respectively, in participants not taking SGLT2i at baseline (HR 0.84; 95% CI 0.74; 0.95; <i>P</i>-interaction 0.66). An analysis of MACE by any in-trial SGLT2i use versus no use also showed no evidence of heterogeneity in the effects of oral semaglutide. The adverse event profiles of oral semaglutide with or without concomitant SGLT2i were similar.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Oral semaglutide reduced MACE outcomes independently of concomitant SGLT2i treatment and this combination appeared to be safe.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40156843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40156843</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.074545>10.1161/CIRCULATIONAHA.125.074545</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40156843</guid>
<pubDate>Sat, 29 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Nikolaus Marx</dc:creator>
<dc:creator>John E Deanfield</dc:creator>
<dc:creator>Johannes F E Mann</dc:creator>
<dc:creator>Rosario Arechavaleta</dc:creator>
<dc:creator>Stephen C Bain</dc:creator>
<dc:creator>Harpreet S Bajaj</dc:creator>
<dc:creator>Katrine Bayer Tanggaard</dc:creator>
<dc:creator>Andreas L Birkenfeld</dc:creator>
<dc:creator>John B Buse</dc:creator>
<dc:creator>Zaklina Davicevic-Elez</dc:creator>
<dc:creator>Cyrus Desouza</dc:creator>
<dc:creator>Scott S Emerson</dc:creator>
<dc:creator>Mads D M Engelmann</dc:creator>
<dc:creator>G Kees Hovingh</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Sharon L Mulvagh</dc:creator>
<dc:creator>Rodica Pop-Busui</dc:creator>
<dc:creator>Neil R Poulter</dc:creator>
<dc:creator>Søren Rasmussen</dc:creator>
<dc:creator>Shih-Te Tu</dc:creator>
<dc:creator>Darren K McGuire</dc:creator>
<dc:creator>SOUL study group</dc:creator>
<dc:date>2025-03-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial</dc:title>
<dc:identifier>pmid:40156843</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.074545</dc:identifier>
</item>
<item>
<title>Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40156827/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: The efficacy of finerenone was consistent regardless of AF status. New-onset AF was associated with a substantially higher risk of subsequent outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 29. doi: 10.1001/jamacardio.2025.0848. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Heart failure (HF) with mildly reduced or preserved ejection fraction and atrial fibrillation (AF) are closely intertwined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with HF with mildly reduced or preserved ejection fraction according to the absence or presence of AF and the type of AF (paroxysmal vs persistent or permanent).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Prespecified analyses were conducted in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial. The trial was conducted across 653 sites in 37 countries. Participants were adults aged 40 years and older with symptomatic HF and left ventricular ejection fraction of 40% or greater, randomized between September 2020 and January 2023. Data analysis was conducted from September 1 to October 1, 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Finerenone (titrated to 20 mg or 40 mg) or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of total HF events and cardiovascular death. New-onset AF or atrial flutter (AFL) was a prespecified exploratory outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 5984 patients (mean [SD] age, 72.0 [9.6] years; 2724 [45.5%] female) with known AF status at baseline, 1384 (23.1%) had paroxysmal AF and 1886 (31.5%) had persistent or permanent AF. Patients with both types of AF were older and had worse HF status compared with those without AF (2714 patients [45.4%]). Both types of AF were associated with a higher unadjusted risk of the primary outcome compared with no AF (event rate per 100 person-years of follow-up, 20.3 [95% CI, 17.9-23.1] with paroxysmal AF, 19.8 [95% CI, 17.8-22.0] with persistent or permanent AF, and 11.9 [95% CI, 10.7-13.3] with no AF; rate ratio [RR], 1.62 [95% CI, 1.37-1.92] with paroxysmal AF and 1.66 [95% CI, 1.43-1.93] with persistent or permanent AF vs no AF); however, the associations were attenuated after adjustment for known prognostic variables. The benefit of finerenone on the primary outcome (overall RR, 0.84 [95% CI, 0.74-0.95]) was not modified by baseline AF status (RR, 0.80 [95% CI, 0.65-0.98] with no AF, 0.83 [95% CI, 0.65-1.06] with paroxysmal AF, and 0.85 [95% CI, 0.69-1.05] with persistent or permanent AF; P for interaction = .94). New-onset AF or AFL occurred in 6.5% of patients and was associated with a higher subsequent adjusted risk of the primary outcome (rate ratio, 3.65 [95% CI, 2.57-5.18]; P &lt; .001). The subdistribution hazard ratio for new-onset AF or AFL among those receiving finerenone vs placebo was 0.77 (95% CI, 0.57-1.04; P = .09).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The efficacy of finerenone was consistent regardless of AF status. New-onset AF was associated with a substantially higher risk of subsequent outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40156827/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40156827</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0848>10.1001/jamacardio.2025.0848</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40156827</guid>
<pubDate>Sat, 29 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Shingo Matsumoto</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Ovidiu Chioncel</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Josep Comin-Colet</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Markus Florian Scheerer</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Flaviana Amarante</dc:creator>
<dc:creator>Meike Brinker</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Shelley Zieroth</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2025-03-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40156827</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0848</dc:identifier>
</item>
<item>
<title>The Role of Cardiovascular Disease Journals in Reporting Sex and Gender in Research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40156098/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 28:ehaf206. doi: 10.1093/eurheartj/ehaf206. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40156098/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40156098</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf206>10.1093/eurheartj/ehaf206</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40156098</guid>
<pubDate>Sat, 29 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>C Noel Bairey Merz</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:creator>Mercedes Carnethon</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Erica S Spatz</dc:creator>
<dc:date>2025-03-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Role of Cardiovascular Disease Journals in Reporting Sex and Gender in Research</dc:title>
<dc:identifier>pmid:40156098</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf206</dc:identifier>
</item>
<item>
<title>Scientific journey from PSCK9 discovery in familial hypercholesterolaemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40155484/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Mar 28. doi: 10.1038/s41569-025-01147-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40155484/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40155484</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01147-w>10.1038/s41569-025-01147-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40155484</guid>
<pubDate>Sat, 29 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Marianne Abifadel</dc:creator>
<dc:date>2025-03-29</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Scientific journey from PSCK9 discovery in familial hypercholesterolaemia</dc:title>
<dc:identifier>pmid:40155484</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01147-w</dc:identifier>
</item>
<item>
<title>Unaddressed questions on the benefits of nationwide abdominal aortic aneurysm screening in Sweden</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40155059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 28:ehaf149. doi: 10.1093/eurheartj/ehaf149. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40155059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40155059</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf149>10.1093/eurheartj/ehaf149</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40155059</guid>
<pubDate>Fri, 28 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Heng Wang</dc:creator>
<dc:creator>Honglin Dong</dc:creator>
<dc:creator>Guoping Zheng</dc:creator>
<dc:date>2025-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Unaddressed questions on the benefits of nationwide abdominal aortic aneurysm screening in Sweden</dc:title>
<dc:identifier>pmid:40155059</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf149</dc:identifier>
</item>
<item>
<title>Abdominal Aortic Aneurysm screening is working but could be targeted to a more specific high-risk population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40155057/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 28:ehaf151. doi: 10.1093/eurheartj/ehaf151. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40155057/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40155057</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf151>10.1093/eurheartj/ehaf151</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40155057</guid>
<pubDate>Fri, 28 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Matti T Laine</dc:creator>
<dc:creator>Kevin Mani</dc:creator>
<dc:creator>Anders Wanhainen</dc:creator>
<dc:date>2025-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Abdominal Aortic Aneurysm screening is working but could be targeted to a more specific high-risk population</dc:title>
<dc:identifier>pmid:40155057</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf151</dc:identifier>
</item>
<item>
<title>European Society of Cardiology Clinical Practice Guidelines: fostering implementation in low-resource settings</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40152908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331210257&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 28:ehaf075. doi: 10.1093/eurheartj/ehaf075. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40152908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331210257&v=2.18.0.post9+e462414">40152908</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf075>10.1093/eurheartj/ehaf075</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40152908</guid>
<pubDate>Fri, 28 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Eva Prescott</dc:creator>
<dc:date>2025-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Society of Cardiology Clinical Practice Guidelines: fostering implementation in low-resource settings</dc:title>
<dc:identifier>pmid:40152908</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf075</dc:identifier>
</item>





























</channel>
</rss>